The Impact of Adjuvant Radiation Therapy for High-Grade Gliomas by Histology in the United States Population

2014 ◽  
Vol 90 (4) ◽  
pp. 894-902 ◽  
Author(s):  
Chad G. Rusthoven ◽  
Julie A. Carlson ◽  
Timothy V. Waxweiler ◽  
Miranda J. Dally ◽  
Anna E. Barón ◽  
...  
Keyword(s):  
United States ◽  
Radiation Therapy ◽  
The United States ◽  
Adjuvant Radiation ◽  
High Grade ◽  
Adjuvant Radiation Therapy ◽  
United States Population ◽  
High Grade Gliomas ◽  
The Impact

The Role of Adjuvant Radiation Therapy in the Management of High-Grade Gliomas

2012 ◽  
Vol 23 (2) ◽  
pp. 247-258 ◽  
Author(s):  
Joshua J. Wind ◽  
Richard Young ◽  
Ashima Saini ◽  
Jonathan H. Sherman
Keyword(s):  
Radiation Therapy ◽  
Adjuvant Radiation ◽  
High Grade ◽  
Adjuvant Radiation Therapy ◽  
High Grade Gliomas

scholarly journals Use of Adjuvant Radiation Therapy in Node-positive Melanoma in the United States

2015 ◽  
Vol 93 (3) ◽  
pp. E369-E370
Author(s):  
A. Orton ◽  
J. Hyngstrom ◽  
R.H.I. Andtbacka ◽  
T. Bowles ◽  
K. Grossmann ◽  
...  
Keyword(s):  
United States ◽  
Radiation Therapy ◽  
The United States ◽  
Adjuvant Radiation ◽  
Adjuvant Radiation Therapy ◽  
Node Positive

Aggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment

2017 ◽  
Vol 126 (7) ◽  
pp. 525-529 ◽  
Author(s):  
Robert W. Eppsteiner ◽  
Jonathan W. Fowlkes ◽  
Carryn M. Anderson ◽  
Robert A. Robinson ◽  
Nitin A. Pagedar
Keyword(s):  
Radiation Therapy ◽  
Early Stage ◽  
Relative Survival ◽  
Carcinoma Ex Pleomorphic Adenoma ◽  
Adjuvant Radiation ◽  
Major Salivary Gland ◽  
High Grade ◽  
Duct Carcinoma ◽  
The Impact ◽  
Case Basis

Background: Few studies have examined whether the use of adjuvant treatment impacts survival for early stage high-grade salivary tumors. Methods: A retrospective review of the SEER database between 1973 and 2012 was performed. Patients with high-grade major salivary gland tumors including salivary duct carcinoma, carcinoma ex-pleomorphic adenoma, high-grade mucoepidermoid carcinoma, or adenocarcinoma, NOS were identified. Only stage I-II tumors were included. The impact of radiation status on observed and relative survival was examined. Results: Five hundred seventy-four patients with high-grade, early stage salivary tumors met inclusion criteria. Sixty-seven percent of patients received radiation therapy. There was no difference in observed or relative survival based on having received radiation. Conclusions: Adjuvant radiation is indicated for advanced stage tumors or early stage tumors with adverse features. For early stage tumors without adverse features, there was no survival benefit from radiation therapy. Adjuvant radiation should be decided on a case-by-case basis for these patients.

Impact of the extent of resection on primary breast angiosarcoma survival.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 521-521
Author(s):  
Timur Mitin ◽  
Shearwood McClelland ◽  
Jess Hatfield ◽  
Catherine Degnin ◽  
Yiyi Chen
Keyword(s):  
United States ◽  
Surgical Resection ◽  
Tumor Size ◽  
Extent Of Resection ◽  
The United States ◽  
Adjuvant Radiation ◽  
Cancer Data ◽  
Surgical Modality ◽  
The Impact ◽  
Related Mortality

521 Background: The widely accepted standard of care in treating primary breast angiosarcoma involves surgical resection, often followed by adjuvant therapy (radiation and/or chemotherapy). The rarity of this disease has precluded large-scale analyses. The question regarding the impact of resection extent on survival has yet to be examined on a nationwide scale. Methods: The National Cancer Data Base (NCDB) from 2004-2014 identified primary breast angiosarcoma patients throughout the United States having undergone surgical resection. The extent of resection (mastectomy versus lumpectomy) was adjusted for several variables (including patient age, race, income, primary payer for care, tumor size, adjuvant therapies, and medical comorbidities) to assess its impact on breast angiosarcoma-related mortality. Results: Over this eleven-year span, 826 resected primary breast angiosarcoma patients were identified in the United States. Mastectomy was by far the most common surgical modality for primary breast angiosarcoma (86% of patients). Increasing tumor size was predictive for mastectomy over lumpectomy (p < 0.0001), and for involvement of adjuvant radiation therapy (p = 0.001). The extent of surgical resection was inversely predictive of radiation usage (p = 0.017). However, surgical modality was not significantly predictive of breast angiosarcoma-related mortality. Conclusions: Despite the frequent preference of mastectomy for primary breast angiosarcoma treatment (more than 6 of every 7 patients), there is no survival benefit of mastectomy versus lumpectomy. This lack of benefit should be discussed with patients, given the reduced operative morbidity of lumpectomy versus mastectomy. The Class IIB evidence provided from this analysis represents the highest level of evidence to-date governing management of this disease.

scholarly journals Primary and secondary breast angiosarcoma: single center report and a meta-analysis

2019 ◽  
Vol 178 (3) ◽  
pp. 523-533 ◽  
Author(s):  
Yara Abdou ◽  
Ahmed Elkhanany ◽  
Kristopher Attwood ◽  
Wenyan Ji ◽  
Kazuaki Takabe ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Adjuvant Chemotherapy ◽  
Tumor Size ◽  
Meta Analysis ◽  
Systemic Review ◽  
Comprehensive Cancer Center ◽  
Survival Outcomes ◽  
Adjuvant Radiation ◽  
High Grade ◽  
Adjuvant Radiation Therapy

Abstract Background Primary and secondary breast angiosarcoma is a rare and aggressive malignancy with limited published literature. Optimal management is mostly based on expert opinion. Our study aims to describe a single institution experience with breast angiosarcoma and evaluate other publications on this topic to further clarify prognostic outcomes and treatment modalities in this disease. Methods Twenty two cases of breast angiosarcoma from Roswell Park Comprehensive Cancer Center were retrospectively analyzed. Additionally, a systemic review and meta-analysis was conducted to study the association between survival outcomes, overall survival (OS), and recurrence-free survival (RFS) in both primary (PAS) and secondary breast angiosarcoma (SAS). Results 9 PAS patients (41%) and 13 SAS patients (59%) were retrospectively analyzed. No significant differences were noted in tumor characteristics and survival outcomes between PAS and SAS. Treatment modality had no significant effects on survival outcomes although adjuvant chemotherapy demonstrated a trend towards improved RFS in high grade tumors. 380 PAS and 595 SAS patients were included in the outcome meta-analysis. Survival outcomes were significantly worse with high grade tumors and tumor size of > 5 cm. Adjuvant radiation therapy demonstrated significantly better RFS, while adjuvant chemotherapy had no effect on survival outcomes. Conclusion Tumor size and grade seem to be reliable predictors of survival in both PAS and SAS. Mastectomy does not seem to be adding any additional benefit to BCS. Adjuvant radiation therapy showed statistically significant RFS benefit, while adjuvant chemotherapy can be beneficial in high grade tumors.

Sign in / Sign up

Export Citation Format

Share Document